01 January 2026 | News
Image Courtesy: Public Domain
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced a new strategic manufacturing partnership with Syrma Johari MedTech Ltd. (“Syrma Johari”), a globally recognized medical device engineering and manufacturing organization with over 45 years of experience, to support and scale the production of its Intelligent Fingerprinting Drug Screening Reader. The collaboration is also expected to support long-term margin improvement.
The partnership is expected to deliver significant operational and financial benefits for the Company. INBS anticipates annual production cost savings of more than 40%, translating to an expected improvement of approximately 20 percentage points in gross margin compared with its previous manufacturing arrangement. Additionally, Syrma Johari’s manufacturing capacity is approximately four times INBS’ current capacity, positioning the Company to efficiently support anticipated demand as it scales commercial operations.
The partnership strengthens INBS' global manufacturing strategy, reducing reliance on a single supplier and building greater resilience into its supply chain. It further broadens capacity, ensures continuity, and creates flexibility as the Company prepares for anticipated future demand across multiple regions and planned U.S. market entry in 2026.
Syrma Johari brings a deep and proven track record in the design, engineering, and production of regulated medical technology devices. It operates 14 manufacturing locations and four design and innovation centres across India, Europe, and the United States, with a combined plant area of over 1.1 million sq. ft. Syrma Johari is fully certified to ISO 13485, MDSAP, FDA, TUV SUD, and GMP standards, ensuring world-class compliance and quality in medical device manufacturing.
Syrma Johari’s scale, vertical integration, and export-oriented operating model enable high-quality production while creating efficiencies in sourcing, tooling, testing, and logistics. Its expertise in electronics, mechanical assembly, PCB manufacturing, functional testing, and clean-room processes positions them to produce INBS' fingerprint drug-screening reader to a consistently high standard, while delivering cost advantages over time. As Syrma Johari prepares to open its new medical-grade plastics manufacturing facility in India in January 2026, it is further expanding its capabilities to meet growing global demand and provide international clients with a strategically located, reliable manufacturing alternative in Asia.
Syrma Johari’s extensive regulatory and quality-assurance capabilities further align with INBS' global expansion plans. It provides end-to-end quality systems, regulatory documentation support, and compliance processes designed to meet the requirements of major jurisdictions, including the U.S., Europe, Canada, the UK, and key Asia-Pacific markets. This depth of experience will support INBS as it continues advancing its regulatory pathways and prepares for increased commercial activity worldwide.
“Partnering with Syrma Johari is a strategically significant milestone for our business,” said Callistus Sequeira, Vice President of Global Quality and Operations at Intelligent Bio Solutions. “Its global footprint, manufacturing excellence, and proven track record in regulated medical devices make it an outstanding partner as we scale production of our Drug Screening Reader. This collaboration strengthens our supply chain, supports future growth, and enhances our ability to deliver reliable, high-quality products to customers around the world.”
Syrma Johari’s leadership shared a similar sentiment, noting that the partnership reflects a strong alignment in innovation, quality, and long-term vision, and that it is pleased to support INBS in scaling a disruptive drug-screening technology with global potential.
“Partnering with Intelligent Bio Solutions is an exciting opportunity to apply our engineering strength, manufacturing scale, and quality systems to a breakthrough technology with global potential,” said Pankaj Wadke, Head International Sales & Business Development at Syrma Johari MedTech Ltd. “At Syrma Johari MedTech, we are committed to enabling innovative solutions that make a meaningful impact, and we look forward to supporting INBS as they expand access to this disruptive, non-invasive drug-screening platform.”
